ZUMA-1 Phase 1/2 trial

February 26, 2019

Yescarta Approved in Canada for Adults with Relapsed or Refractory Large B-cell Lymphoma

News

Health Canada has approved Yescarta (axicabtagene ciloleucel) as a treatment for adults with diffuse large B-cell lymphoma (DLBCL) who have already received two or more lines of systemic therapy. Specifically, ... Read more

December 12, 2018

Follow-up Trial Results Reinforce Yescarta as Relapsed Non-Hodgkin’s Lymphoma Therapy

News

More than two years after receiving treatment with Yescarta (axicabtagene ciloleucel), 51% of non-Hodgkin’s lymphoma patients included in the ZUMA-1 Phase 1/2 clinical trial are still alive, and 39% are ... Read more

May 24, 2018

New Collaboration will Study Long-term Outcomes of CAR T-cell Therapy Yescarta

News

The Center for International Blood and Marrow Transplant Research (CIBMTR) and Kite Pharma recently agreed to collaborate on tracking long-term outcomes of patients treated with Yescarta (axicabtagene ciloleucel), a chimeric antigen receptor ... Read more

January 19, 2018January 19, 2018

Phase 1/2 Trial to Test Yescarta-Utomilumab Combo in Refractory Large B-cell Lymphoma

News

A new multicenter Phase 1/2 trial will evaluate an immunotherapy combination of Yescarta (axicabtagene ciloleucel) and utomilumab for the treatment of patients with refractory large B-cell lymphoma. The trial, part of a clinical ... Read more

December 13, 2017

40% of Relapsed NHL Patients Remain Cancer-free a Year After Treatment with Kite’s Yescarta

News

More than a year after receiving the CAR T-cell therapy Yescarta (axicabtagene ciloleucel), 42 percent of the patients in the ZUMA-1 trial are still responding to the treatment, Kite Pharma announced. The Phase ... Read more

July 12, 2017July 12, 2017

Lymphoma Therapy Developer Kite Is Number 7 on MIT Technology Review’s List of 50 Smartest Companies

News

Kite Pharma is ranked #7 on MIT Technology Review’s list of the 50 Smartest Companies for its pioneering work in engineered cell therapy for treating cancer. The company received the recognition for ... Read more

July 7, 2017July 7, 2017

Response to Kite’s CAR T-Cell Therapy in NHL Isn’t Dependent on Disease Factors, Researchers Say

News

The ZUMA-1 Phase 2 clinical trial of the CAR T-cell therapy axicabtagene ciloleucel (KTE-C19) showed that 82% of patients with treatment-resistant or relapsed aggressive non-Hodgkin’s lymphoma (NHL) responded to the ... Read more

May 30, 2017

FDA to Review Kite’s Application for CAR T-Cell Therapy to Treat Aggressive Non-Hodgkin’s Lymphoma

News

The U.S. Food and Drug Administration (FDA) has accepted for review the biologics license application (BLA) seeking the approval of axicabtagene ciloleucel (KTE-C19) for the treatment of refractory aggressive non-Hodgkin’s ... Read more

April 6, 2017

Kite Presents Positive Data from ZUMA-1 Trial in Aggressive Non-Hodgkin’s Lymphoma Patients

News

ZUMA-1, Kite Pharma‘s Phase 1/2 trial assessing the CAR T-cell therapy axicabtagene ciloleucel in patients with aggressive B-cell non-Hodgkin’s lymphoma has reached its primary endpoint of objective response rate, according ... Read more

January 9, 2017

New CAR T-cell Therapy Shows ‘Remarkable’ Promise for Highly Refractory Lymphoma

News

Patients with refractory diffuse large B-cell lymphoma (DLBCL) could greatly benefit from a new CAR T-cell therapy called KTE-C19, according to recently published data from the Phase 1 ZUMA-1 trial. ... Read more